{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:38:32Z","timestamp":1792669112859,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01057-0","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:42:13Z","timestamp":1792665733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clobazam Use in Epilepsy: An Old Story with a New Twist. A Narrative Review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3967-1065","authenticated-orcid":false,"given":"Simone","family":"Gasparini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7272-7079","authenticated-orcid":false,"given":"Renzo","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"1057_CR1","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2468-2667(24)00302-5","volume":"10","author":"VL Feigin","year":"2025","unstructured":"Feigin VL, Vos T, Nair BS, et al. Global, regional, and national burden of epilepsy, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Public Health. 2025;10:e203\u201327. https:\/\/doi.org\/10.1016\/S2468-2667(24)00302-5.","journal-title":"Lancet Public Health"},{"key":"1057_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2165\/11599020-000000000-00000","volume":"26","author":"R Sankar","year":"2012","unstructured":"Sankar R. GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs. 2012;26:229\u201344. https:\/\/doi.org\/10.2165\/11599020-000000000-00000.","journal-title":"CNS Drugs"},{"key":"1057_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088456","volume":"9","author":"HS Jensen","year":"2014","unstructured":"Jensen HS, Nichol K, Lee D, Ebert B. Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for \u03b12- versus \u03b11-GABAA-receptor complexes. PLoS ONE. 2014;9:e88456. https:\/\/doi.org\/10.1371\/journal.pone.0088456.","journal-title":"PLoS ONE"},{"key":"1057_CR4","doi-asserted-by":"publisher","first-page":"151S","DOI":"10.1111\/j.1365-2125.1979.tb04685.x","volume":"7","author":"GW Hanks","year":"1979","unstructured":"Hanks GW. Clobazam. Br J Clin Pharmacol. 1979;7:151S-155S. https:\/\/doi.org\/10.1111\/j.1365-2125.1979.tb04685.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1057_CR5","doi-asserted-by":"publisher","first-page":"109S","DOI":"10.1111\/j.1365-2125.1979.tb04675.x","volume":"7","author":"HH Wieck","year":"1979","unstructured":"Wieck HH, Blaha L, Heerklotz B. A clinical view of clobazam. Br J Clin Pharmacol. 1979;7:109S-112S. https:\/\/doi.org\/10.1111\/j.1365-2125.1979.tb04675.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1057_CR6","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1528-1157.1979.tb04825.x","volume":"20","author":"H Gastaut","year":"1979","unstructured":"Gastaut H, Low MD. Antiepileptic properties of clobazam, a 1\u20135 benzodiazepine, in man. Epilepsia. 1979;20:437\u201346. https:\/\/doi.org\/10.1111\/j.1528-1157.1979.tb04825.x.","journal-title":"Epilepsia"},{"key":"1057_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.110183","volume":"163","author":"G Scorrano","year":"2025","unstructured":"Scorrano G, Delattre C, Leiber AE, Nabbout R. Evaluating the patient needs and tolerability of clobazam liquid formulation (Likozam\u00ae 1\u00a0mg\/mL): a French patient and care-givers\u2019 centered survey. Epilepsy Behav EB. 2025;163:110183. https:\/\/doi.org\/10.1016\/j.yebeh.2024.110183.","journal-title":"Epilepsy Behav EB"},{"key":"1057_CR8","doi-asserted-by":"publisher","DOI":"10.4081\/pr.2016.6516","volume":"8","author":"M Pernea","year":"2016","unstructured":"Pernea M, Sutcliffe AG. Clobazam and its use in epilepsy. Pediatr Rep. 2016;8:6516. https:\/\/doi.org\/10.4081\/pr.2016.6516.","journal-title":"Pediatr Rep"},{"key":"1057_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161660","volume":"11","author":"JH D\u00f6ring","year":"2016","unstructured":"D\u00f6ring JH, Lampert A, Hoffmann GF, Ries M. Thirty years of orphan drug legislation and the development of drugs to treat rare seizure conditions: a cross sectional analysis. PLoS ONE. 2016;11:e0161660. https:\/\/doi.org\/10.1371\/journal.pone.0161660.","journal-title":"PLoS ONE"},{"key":"1057_CR10","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","volume":"77","author":"YT Ng","year":"2011","unstructured":"Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA, OV-1012 Study Investigators. Randomized, phase\u00a0III study results of clobazam in Lennox\u2013Gastaut syndrome. Neurology. 2011;77:1473\u201381. https:\/\/doi.org\/10.1212\/WNL.0b013e318232de76.","journal-title":"Neurology"},{"key":"1057_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/1756285614521314","volume":"7","author":"G Purcarin","year":"2014","unstructured":"Purcarin G, Ng Y-T. Experience in the use of clobazam in the treatment of Lennox\u2013Gastaut syndrome. Ther Adv Neurol Disord. 2014;7:169\u201376. https:\/\/doi.org\/10.1177\/1756285614521314.","journal-title":"Ther Adv Neurol Disord"},{"key":"1057_CR12","unstructured":"Epidyolex | European Medicines Agency (EMA). 2019. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/epidyolex. Accessed 20 Mar 2026."},{"key":"1057_CR13","unstructured":"Diacomit | European Medicines Agency (EMA). 2014. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/diacomit. Accessed 20 Mar 2026."},{"key":"1057_CR14","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1111\/epi.17274","volume":"63","author":"EC Wirrell","year":"2022","unstructured":"Wirrell EC, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022;63:1761\u201377. https:\/\/doi.org\/10.1111\/epi.17274.","journal-title":"Epilepsia"},{"key":"1057_CR15","unstructured":"Search Orphan Drug Designations and Approvals. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=266108. Accessed 19 July 2026."},{"issue":"Suppl 1","key":"1057_CR16","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1111\/j.1528-1157.1986.tb05729.x","volume":"27","author":"P Tinuper","year":"1986","unstructured":"Tinuper P, Aguglia U, Gastaut H. Use of clobazam in certain forms of status epilepticus and in startle-induced epileptic seizures. Epilepsia. 1986;27(Suppl 1):S18-26. https:\/\/doi.org\/10.1111\/j.1528-1157.1986.tb05729.x.","journal-title":"Epilepsia"},{"key":"1057_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.82.10_supplement.P3.281","volume":"82","author":"D Jones","year":"2014","unstructured":"Jones D, Isojarvi J, Guiraud-Diawara A, Shen V, Verpillat P. Differences in usage of clobazam vs. clonazepam for epilepsy (P3.281). Neurology. 2014;82:P3.281. https:\/\/doi.org\/10.1212\/WNL.82.10_supplement.P3.281.","journal-title":"Neurology"},{"key":"1057_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.eplepsyres.2016.04.003","volume":"123","author":"MJ Brodie","year":"2016","unstructured":"Brodie MJ, Chung S, Wade A, et al. Clobazam and clonazepam use in epilepsy: results from a UK database incident user cohort study. Epilepsy Res. 2016;123:68\u201374. https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.04.003.","journal-title":"Epilepsy Res"},{"key":"1057_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1365-2125.1990.tb03616.x","volume":"29","author":"JD Wildin","year":"1990","unstructured":"Wildin JD, Pleuvry BJ, Mawer GE, Onon T, Millington L. Respiratory and sedative effects of clobazam and clonazepam in volunteers. Br J Clin Pharmacol. 1990;29:169\u201377. https:\/\/doi.org\/10.1111\/j.1365-2125.1990.tb03616.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1057_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jchromb.2005.06.031","volume":"823","author":"M Rouini","year":"2005","unstructured":"Rouini M, Ardakani YH, Hakemi L, Mokhberi M, Badri G. Simultaneous determination of clobazam and its major metabolite in human plasma by a rapid HPLC method. J Chromatogr B Anal Technol Biomed Life Sci. 2005;823:167\u201371. https:\/\/doi.org\/10.1016\/j.jchromb.2005.06.031.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"1057_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2019.106182","volume":"157","author":"D Tolbert","year":"2019","unstructured":"Tolbert D, Chu H-M, Ette EI. Pharmacometrics of clobazam in pediatrics: prediction of effective clobazam doses for Dravet syndrome. Epilepsy Res. 2019;157:106182. https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.106182.","journal-title":"Epilepsy Res"},{"key":"1057_CR22","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/j.1365-2125.1984.tb02558.x","volume":"18","author":"S Jawad","year":"1984","unstructured":"Jawad S, Richens A, Oxley J. Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients. Br J Clin Pharmacol. 1984;18:873\u20137. https:\/\/doi.org\/10.1111\/j.1365-2125.1984.tb02558.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1057_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jcph.1313","volume":"59","author":"D Tolbert","year":"2019","unstructured":"Tolbert D, Larsen F. A comprehensive overview of the clinical pharmacokinetics of clobazam. J Clin Pharmacol. 2019;59:7\u201319. https:\/\/doi.org\/10.1002\/jcph.1313.","journal-title":"J Clin Pharmacol"},{"key":"1057_CR24","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","volume":"32","author":"C Giraud","year":"2004","unstructured":"Giraud C, Tran A, Rey E, Vincent J, Tr\u00e9luyer J-M, Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004;32:1279\u201386.","journal-title":"Drug Metab Dispos"},{"key":"1057_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3848","author":"T Iwasaki","year":"2017","unstructured":"Iwasaki T, Nonoda Y, Ishida T, Toki T, Ishii M. Correlating blood and urinary concentrations of clobazam doses in Japanese children and adolescents with intractable epilepsy. Biomed Chromatogr. 2017. https:\/\/doi.org\/10.1002\/bmc.3848.","journal-title":"Biomed Chromatogr"},{"key":"1057_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/FPC.0000000000000327","volume":"28","author":"R Huddart","year":"2018","unstructured":"Huddart R, Leeder JS, Altman RB, Klein TE. PharmGKB summary: clobazam pathway, pharmacokinetics. Pharmacogenet Genomics. 2018;28:110\u20135. https:\/\/doi.org\/10.1097\/FPC.0000000000000327.","journal-title":"Pharmacogenet Genomics"},{"issue":"Suppl 1","key":"1057_CR27","doi-asserted-by":"publisher","first-page":"41S","DOI":"10.1111\/j.1365-2125.1979.tb04664.x","volume":"7","author":"M Volz","year":"1979","unstructured":"Volz M, Christ O, Kellner HM, et al. Kinetics and metabolism of clobazam in animals and man. Br J Clin Pharmacol. 1979;7(Suppl 1):41S-50S. https:\/\/doi.org\/10.1111\/j.1365-2125.1979.tb04664.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1057_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-2125.1987.tb03032.x","volume":"23","author":"JR Haigh","year":"1987","unstructured":"Haigh JR, Pullar T, Gent JP, Dailley C, Feely M. N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy. Br J Clin Pharmacol. 1987;23:213\u20138. https:\/\/doi.org\/10.1111\/j.1365-2125.1987.tb03032.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1057_CR29","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S0090-9556(25)08020-1","volume":"11","author":"RH Levy","year":"1983","unstructured":"Levy RH, Lane EA, Guyot M, Brachet-Liermain A, Cenraud B, Loiseau P. Analysis of parent drug-metabolite relationship in the presence of an inducer. Application to the carbamazepine-clobazam interaction in normal man. Drug Metab Dispos. 1983;11:286\u201392.","journal-title":"Drug Metab Dispos"},{"key":"1057_CR30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3851\/IMP1953","volume":"17","author":"M Naccarato","year":"2012","unstructured":"Naccarato M, Yoong D, Kovacs C, Gough K. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir Ther. 2012;17:589\u201392. https:\/\/doi.org\/10.3851\/IMP1953.","journal-title":"Antivir Ther"},{"key":"1057_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.yebeh.2014.03.018","volume":"34","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Takahashi Y, Imai K, et al. Interaction between sulthiame and clobazam: sulthiame inhibits the metabolism of clobazam, possibly via an action on CYP2C19. Epilepsy Behav. 2014;34:124\u20136. https:\/\/doi.org\/10.1016\/j.yebeh.2014.03.018.","journal-title":"Epilepsy Behav"},{"key":"1057_CR32","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1124\/dmd.105.007237","volume":"34","author":"C Giraud","year":"2006","unstructured":"Giraud C, Treluyer J-M, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34:608\u201311. https:\/\/doi.org\/10.1124\/dmd.105.007237.","journal-title":"Drug Metab Dispos"},{"key":"1057_CR33","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1111\/epi.16355","volume":"60","author":"LL Anderson","year":"2019","unstructured":"Anderson LL, Absalom NL, Abelev SV, et al. Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia. 2019;60:2224\u201334. https:\/\/doi.org\/10.1111\/epi.16355.","journal-title":"Epilepsia"},{"key":"1057_CR34","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1111\/epi.17515","volume":"64","author":"S Elakkary","year":"2023","unstructured":"Elakkary S, Hagemann A, Klimpel D, Bien CG, Brandt C. A retrospective non-interventional study evaluating the pharmacokinetic interactions between cenobamate and clobazam. Epilepsia. 2023;64:e36-42. https:\/\/doi.org\/10.1111\/epi.17515.","journal-title":"Epilepsia"},{"key":"1057_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109156","volume":"142","author":"M Osborn","year":"2023","unstructured":"Osborn M, Abou-Khalil B. The cenobamate-clobazam interaction- evidence of synergy in addition to pharmacokinetic interaction. Epilepsy Behav EB. 2023;142:109156. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109156.","journal-title":"Epilepsy Behav EB"},{"key":"1057_CR36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","volume":"32","author":"M Walzer","year":"2012","unstructured":"Walzer M, Bekersky I, Blum RA, Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy. 2012;32:340\u201353. https:\/\/doi.org\/10.1002\/j.1875-9114.2012.01028.x.","journal-title":"Pharmacotherapy"},{"key":"1057_CR37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/cns.12399","volume":"21","author":"AC Gauthier","year":"2015","unstructured":"Gauthier AC, Mattson RH. Clobazam: a safe, efficacious, and newly rediscovered therapeutic for epilepsy. CNS Neurosci Ther. 2015;21:543\u20138. https:\/\/doi.org\/10.1111\/cns.12399.","journal-title":"CNS Neurosci Ther"},{"key":"1057_CR38","unstructured":"Dean L. Clobazam Therapy and CYP2C19 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Med Genet Summ. Bethesda (MD): National Center for Biotechnology Information (US); 2012. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK546789\/. Accessed 21 Mar 2026."},{"key":"1057_CR39","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1124\/mol.105.017236","volume":"69","author":"S Khom","year":"2006","unstructured":"Khom S, Baburin I, Timin EN, Hohaus A, Sieghart W, Hering S. Pharmacological properties of GABAA receptors containing gamma1 subunits. Mol Pharmacol. 2006;69:640\u20139. https:\/\/doi.org\/10.1124\/mol.105.017236.","journal-title":"Mol Pharmacol"},{"key":"1057_CR40","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s12031-015-0495-8","volume":"56","author":"P Nikas","year":"2015","unstructured":"Nikas P, Gatta E, Cupello A, et al. Study of the interaction of 1,4- and 1,5-benzodiazepines with GABAA receptors of rat cerebellum granule cells in culture. J Mol Neurosci. 2015;56:768\u201372. https:\/\/doi.org\/10.1007\/s12031-015-0495-8.","journal-title":"J Mol Neurosci"},{"key":"1057_CR41","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.neuroscience.2010.01.013","volume":"166","author":"E Gatta","year":"2010","unstructured":"Gatta E, Cupello A, Di Braccio M, et al. New 1,5-benzodiazepine compounds: activity at native GABA(A) receptors. Neuroscience. 2010;166:917\u201323. https:\/\/doi.org\/10.1016\/j.neuroscience.2010.01.013.","journal-title":"Neuroscience"},{"key":"1057_CR42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.nurt.2006.11.002","volume":"4","author":"Y Ng","year":"2007","unstructured":"Ng Y, Collins SD. Clobazam. Neurotherapeutics. 2007;4:138\u201344. https:\/\/doi.org\/10.1016\/j.nurt.2006.11.002.","journal-title":"Neurotherapeutics"},{"key":"1057_CR43","unstructured":"Apotex Standard: https:\/\/pdf.hres.ca\/dpd_pm\/00060946.PDF. Product monograph. 2021. https:\/\/pdf.hres.ca\/dpd_pm\/00060946.PDF. Accessed 3 May\u00a02026."},{"key":"1057_CR44","unstructured":"Epilepsy Foundation https:\/\/www.epilepsy.com\/stories\/fda-warns-serious-skin-reactions-onfi-and-has-approved-label-change. FDA warns of serious skin reactions in Onfi and has approved label change. 2013. https:\/\/www.epilepsy.com\/stories\/fda-warns-serious-skin-reactions-onfi-and-has-approved-label-change. Accessed 21 Mar 2026."},{"key":"1057_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.yebeh.2014.05.016","volume":"37","author":"D Tolbert","year":"2014","unstructured":"Tolbert D, Harris SI, Bekersky I, Lee D, Isojarvi J. Withdrawal-related adverse events from clinical trials of clobazam in Lennox\u2013Gastaut syndrome. Epilepsy Behav EB. 2014;37:11\u20135. https:\/\/doi.org\/10.1016\/j.yebeh.2014.05.016.","journal-title":"Epilepsy Behav EB"},{"key":"1057_CR46","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1528-1157.1991.tb04670.x","volume":"32","author":"Canadian Clobazam Cooperative Group","year":"1991","unstructured":"Canadian Clobazam Cooperative Group. Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia. 1991;32:407\u201316.","journal-title":"Epilepsia"},{"key":"1057_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100849","author":"J Christensen","year":"2024","unstructured":"Christensen J, Zoega H, Leinonen MK, et al. Prenatal exposure to antiseizure medications and fetal growth: a population-based cohort study from the Nordic countries. Lancet Reg Health Eur. 2024. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100849.","journal-title":"Lancet Reg Health Eur"},{"key":"1057_CR48","unstructured":"Navrax pharmaceuticals. Tapclob-prescribing information. 2019. https:\/\/www.navrax-pharmaceuticals.com\/wp-content\/uploads\/sites\/3\/2019\/07\/TAPCLOB-PI.pdf. Accessed 3 May\u00a02026."},{"key":"1057_CR49","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40120-022-00400-5","volume":"11","author":"MC Smith","year":"2022","unstructured":"Smith MC, Klein P, Krauss GL, et al. Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations. Neurol Ther. 2022;11:1705\u201320. https:\/\/doi.org\/10.1007\/s40120-022-00400-5.","journal-title":"Neurol Ther"},{"key":"1057_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/FTD.0b013e31827ada88","volume":"35","author":"J de Leon","year":"2013","unstructured":"de Leon J, Spina E, Diaz FJ. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit. 2013;35:30\u201347. https:\/\/doi.org\/10.1097\/FTD.0b013e31827ada88.","journal-title":"Ther Drug Monit"},{"key":"1057_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004154.pub5","volume":"10","author":"R Bresnahan","year":"2019","unstructured":"Bresnahan R, Martin-McGill KJ, Williamson J, Michael BD, Marson AG. Clobazam add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev. 2019;10:CD004154. https:\/\/doi.org\/10.1002\/14651858.CD004154.pub5.","journal-title":"Cochrane Database Syst Rev"},{"key":"1057_CR52","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1136\/bmj.286.6373.1246","volume":"286","author":"JW Allen","year":"1983","unstructured":"Allen JW, Oxley J, Robertson MM, Trimble MR, Richens A, Jawad SS. Clobazam as adjunctive treatment in refractory epilepsy. BMJ. 1983;286:1246\u20137. https:\/\/doi.org\/10.1136\/bmj.286.6373.1246.","journal-title":"BMJ"},{"key":"1057_CR53","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/archneur.1986.00520080064023","volume":"43","author":"D Schmidt","year":"1986","unstructured":"Schmidt D, Rohde M, Wolf P, Roeder-Wanner U. Clobazam for refractory focal epilepsy. A controlled trial Arch Neurol. 1986;43:824\u20136. https:\/\/doi.org\/10.1001\/archneur.1986.00520080064023.","journal-title":"A controlled trial Arch Neurol"},{"key":"1057_CR54","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1528-1157.1987.tb03678.x","volume":"28","author":"D Koeppen","year":"1987","unstructured":"Koeppen D, Baruzzi A, Capozza M, et al. Clobazam in therapy-resistant patients with partial epilepsy: a double-blind placebo-controlled crossover study. Epilepsia. 1987;28:495\u2013506. https:\/\/doi.org\/10.1111\/j.1528-1157.1987.tb03678.x.","journal-title":"Epilepsia"},{"key":"1057_CR55","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1017\/s0317167100030651","volume":"17","author":"DL Keene","year":"1990","unstructured":"Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci J Can Sci Neurol. 1990;17:317\u20139. https:\/\/doi.org\/10.1017\/s0317167100030651.","journal-title":"Can J Neurol Sci J Can Sci Neurol"},{"key":"1057_CR56","doi-asserted-by":"publisher","first-page":"e669","DOI":"10.1212\/CPJ.0000000000000992","volume":"11","author":"A Jamil","year":"2021","unstructured":"Jamil A, Levinson N, Gelfand M, Hill CE, Khankhanian P, Davis KA. Efficacy and tolerability of clobazam in adults with drug-refractory epilepsy. Neurol Clin Pract. 2021;11:e669\u201376. https:\/\/doi.org\/10.1212\/CPJ.0000000000000992.","journal-title":"Neurol Clin Pract"},{"key":"1057_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106963","volume":"184","author":"T Kama\u015fak","year":"2022","unstructured":"Kama\u015fak T, Serdaro\u011flu E, Y\u0131lmaz \u00d6, et al. The effectiveness and tolerability of clobazam in the pediatric population: adjunctive therapy and monotherapy in a large-cohort multicenter study. Epilepsy Res. 2022;184:106963. https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.106963.","journal-title":"Epilepsy Res"},{"key":"1057_CR58","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1017\/S0317167100004996","volume":"33","author":"RC Silva","year":"2006","unstructured":"Silva RC, Montenegro MA, Guerreiro CAM, Guerreiro MM. Clobazam as add-on therapy in children with epileptic encephalopathy. Can J Neurol Sci J Can Sci Neurol. 2006;33:209\u201313.","journal-title":"Can J Neurol Sci J Can Sci Neurol"},{"key":"1057_CR59","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/j.1528-1167.2008.01935.x","volume":"50","author":"JA Conry","year":"2009","unstructured":"Conry JA, Ng Y-T, Paolicchi JM, et al. Clobazam in the treatment of Lennox\u2013Gastaut syndrome. Epilepsia. 2009;50:1158\u201366. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01935.x.","journal-title":"Epilepsia"},{"key":"1057_CR60","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/epi.12561","volume":"55","author":"JA Conry","year":"2014","unstructured":"Conry JA, Ng Y-T, Kernitsky L, et al. Stable dosages of clobazam for Lennox\u2013Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3\u00a0years. Epilepsia. 2014;55:558\u201367. https:\/\/doi.org\/10.1111\/epi.12561.","journal-title":"Epilepsia"},{"key":"1057_CR61","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/ane.12086","volume":"128","author":"JA Cramer","year":"2013","unstructured":"Cramer JA, Sapin C, Fran\u00e7ois C. Indirect comparison of clobazam and other therapies for Lennox\u2013Gastaut syndrome. Acta Neurol Scand. 2013;128:91\u20139. https:\/\/doi.org\/10.1111\/ane.12086.","journal-title":"Acta Neurol Scand"},{"key":"1057_CR62","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.pediatrneurol.2012.05.001","volume":"47","author":"AF VanStraten","year":"2012","unstructured":"VanStraten AF, Ng Y-T. Update on the management of Lennox\u2013Gastaut syndrome. Pediatr Neurol. 2012;47:153\u201361. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2012.05.001.","journal-title":"Pediatr Neurol"},{"key":"1057_CR63","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40801-022-00305-7","volume":"9","author":"S Balestrini","year":"2022","unstructured":"Balestrini S, Doccini V, Boncristiano A, Lenge M, De Masi S, Guerrini R. Efficacy and safety of long-term treatment with stiripentol in children and adults with drug-resistant epilepsies: a retrospective cohort study of 196 patients. Drugs - Real World Outcomes. 2022;9:451\u201361. https:\/\/doi.org\/10.1007\/s40801-022-00305-7.","journal-title":"Drugs - Real World Outcomes"},{"key":"1057_CR64","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/14737175.2023.2195550","volume":"23","author":"A Vasquez","year":"2023","unstructured":"Vasquez A, Wirrell EC, Youssef PE. Stiripentol for the treatment of seizures associated with Dravet syndrome in patients 6\u00a0months and older and taking clobazam. Expert Rev Neurother. 2023;23:297\u2013309. https:\/\/doi.org\/10.1080\/14737175.2023.2195550.","journal-title":"Expert Rev Neurother"},{"key":"1057_CR65","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/s0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet. 2000;356:1638\u201342. https:\/\/doi.org\/10.1016\/s0140-6736(00)03157-3.","journal-title":"Lancet"},{"key":"1057_CR66","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1111\/epi.12303","volume":"54","author":"EC Wirrell","year":"2013","unstructured":"Wirrell EC, Laux L, Franz DN, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia. 2013;54:1595\u2013604. https:\/\/doi.org\/10.1111\/epi.12303.","journal-title":"Epilepsia"},{"key":"1057_CR67","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s40120-024-00623-8","volume":"13","author":"R Guerrini","year":"2024","unstructured":"Guerrini R, Chancharme L, Serraz B, Chiron C. Additional results from two randomized, placebo-controlled trials of stiripentol in Dravet syndrome highlight a rapid antiseizure efficacy with longer seizure-free periods. Neurol Ther. 2024;13:869\u201384. https:\/\/doi.org\/10.1007\/s40120-024-00623-8.","journal-title":"Neurol Ther"},{"key":"1057_CR68","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1611618.","journal-title":"N Engl J Med"},{"key":"1057_CR69","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/ane.13351","volume":"143","author":"B Gunning","year":"2021","unstructured":"Gunning B, Mazurkiewicz-Be\u0142dzi\u0144ska M, Chin RFM, et al. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. Acta Neurol Scand. 2021;143:154\u201363. https:\/\/doi.org\/10.1111\/ane.13351.","journal-title":"Acta Neurol Scand"},{"key":"1057_CR70","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.seizure.2025.04.017","volume":"130","author":"MS Perry","year":"2025","unstructured":"Perry MS, Dixon-Salazar T, Meskis MA, et al. Caregiver-reported non-seizure and seizure outcomes with cannabidiol and clobazam in patients aged \u22652\u00a0years with Lennox\u2013Gastaut syndrome or Dravet syndrome: a subgroup analysis of the BECOME survey. Seizure. 2025;130:32\u201340. https:\/\/doi.org\/10.1016\/j.seizure.2025.04.017.","journal-title":"Seizure"},{"key":"1057_CR71","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.seizure.2016.01.006","volume":"35","author":"J Lotte","year":"2016","unstructured":"Lotte J, Bast T, Borusiak P, et al. Effectiveness of antiepileptic therapy in patients with PCDH19 mutations. Seizure. 2016;35:106\u201310. https:\/\/doi.org\/10.1016\/j.seizure.2016.01.006.","journal-title":"Seizure"},{"key":"1057_CR72","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/epi.17886","volume":"65","author":"KM Thalwitzer","year":"2024","unstructured":"Thalwitzer KM, Xian J, de Campo D, et al. Early life seizures and epileptic spasms in STXBP1-related disorders. Epilepsia. 2024;65:805\u201316. https:\/\/doi.org\/10.1111\/epi.17886.","journal-title":"Epilepsia"},{"key":"1057_CR73","doi-asserted-by":"publisher","unstructured":"Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy. Epilepsia. 1998;39:952\u20139. https:\/\/doi.org\/10.1111\/j.1528-1157.1998.tb01444.x.","DOI":"10.1111\/j.1528-1157.1998.tb01444.x"},{"key":"1057_CR74","doi-asserted-by":"crossref","first-page":"581","DOI":"10.33588\/rn.4911.2009525","volume":"49","author":"R Andrade","year":"2009","unstructured":"Andrade R, Garc\u00eda-Espinosa A, Machado-Rojas A, Garc\u00eda-Gonz\u00e1lez ME, Tr\u00e1paga-Quincoses O, Morales-Chac\u00f3n LM. A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. Rev Neurol. 2009;49:581\u20136.","journal-title":"Rev Neurol"},{"key":"1057_CR75","first-page":"1067","volume":"12","author":"O Dulac","year":"1983","unstructured":"Dulac O, Figueroa D, Rey E, Arthuis M. Monotherapy with clobazam in epilepsies in children. Presse Med. 1983;12:1067\u20139.","journal-title":"Presse Med"},{"key":"1057_CR76","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1684\/epd.2022.1468","volume":"24","author":"AA Asadi-Pooya","year":"2022","unstructured":"Asadi-Pooya AA, Patel AA, Trinka E, Mazurkiewicz-Beldzinska M, Cross JH, Welty TE. Recommendations for treatment strategies in people with epilepsy during times of shortage of antiseizure medications. Epileptic Disord. 2022;24:751\u201364. https:\/\/doi.org\/10.1684\/epd.2022.1468.","journal-title":"Epileptic Disord"},{"key":"1057_CR77","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/s0140-6736(82)91691-9","volume":"2","author":"M Feely","year":"1982","unstructured":"Feely M, Calvert R, Gibson J. Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants. Lancet. 1982;2:71\u20133. https:\/\/doi.org\/10.1016\/s0140-6736(82)91691-9.","journal-title":"Lancet"},{"key":"1057_CR78","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/jnnp.47.12.1279","volume":"47","author":"M Feely","year":"1984","unstructured":"Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. J Neurol Neurosurg Psychiatry. 1984;47:1279\u201382. https:\/\/doi.org\/10.1136\/jnnp.47.12.1279.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1057_CR79","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.seizure.2009.09.002","volume":"18","author":"M Almgren","year":"2009","unstructured":"Almgren M, K\u00e4ll\u00e9n B, Lavebratt C. Population-based study of antiepileptic drug exposure in utero\u2014influence on head circumference in newborns. Seizure. 2009;18:672\u20135. https:\/\/doi.org\/10.1016\/j.seizure.2009.09.002.","journal-title":"Seizure"},{"key":"1057_CR80","unstructured":"Antiepileptic drugs: review of safety of use during pregnancy. GOV.UK. https:\/\/www.gov.uk\/government\/publications\/public-assesment-report-of-antiepileptic-drugs-review-of-safety-of-use-during-pregnancy\/antiepileptic-drugs-review-of-safety-of-use-during-pregnancy. Accessed 1 May\u00a02026."},{"key":"1057_CR81","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/epi4.12230","volume":"3","author":"SH Mahmoud","year":"2018","unstructured":"Mahmoud SH, Rans C. Systematic review of clobazam use in patients with status epilepticus. Epilepsia Open. 2018;3:323\u201330. https:\/\/doi.org\/10.1002\/epi4.12230.","journal-title":"Epilepsia Open"},{"key":"1057_CR82","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.seizure.2025.01.005","volume":"125","author":"S Tan","year":"2025","unstructured":"Tan S, Ng JS, Devinuwara J, et al. Management of epilepsia partialis continua: a systematic review. Seizure Eur J Epilep. 2025;125:79\u201383. https:\/\/doi.org\/10.1016\/j.seizure.2025.01.005.","journal-title":"Seizure Eur J Epilep"},{"key":"1057_CR83","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/dmcn.15638","volume":"65","author":"C Chiron","year":"2023","unstructured":"Chiron C, Chemaly N, Chancharme L, Nabbout R. Initiating stiripentol before 2\u00a0years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus. Dev Med Child Neurol. 2023;65:1607\u201316. https:\/\/doi.org\/10.1111\/dmcn.15638.","journal-title":"Dev Med Child Neurol"},{"key":"1057_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108661","volume":"130","author":"J Sullivan","year":"2022","unstructured":"Sullivan J, Deighton AM, Vila MC, et al. The clinical, economic, and humanistic burden of Dravet syndrome\u2014a systematic literature review. Epilepsy Behav EB. 2022;130:108661. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108661.","journal-title":"Epilepsy Behav EB"},{"key":"1057_CR85","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1212\/WNL.0000000000012744","volume":"97","author":"R Guerrini","year":"2021","unstructured":"Guerrini R, Balestrini S, Wirrell EC, Walker MC. Monogenic epilepsies: disease mechanisms, clinical phenotypes, and targeted therapies. Neurology. 2021;97:817\u201331. https:\/\/doi.org\/10.1212\/WNL.0000000000012744.","journal-title":"Neurology"},{"key":"1057_CR86","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70530","volume":"33","author":"T Pisano","year":"2026","unstructured":"Pisano T, Balestrini S, Boncristiano A, et al. Real-world use of cenobamate in paediatric drug-resistant epilepsy: long-term efficacy, safety, and co-medication adjustment. Eur J Neurol. 2026;33:e70530. https:\/\/doi.org\/10.1111\/ene.70530.","journal-title":"Eur J Neurol"},{"key":"1057_CR87","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200151","volume":"10","author":"PJ Serrano-Castro","year":"2023","unstructured":"Serrano-Castro PJ, Rodr\u00edguez-Uranga JJ, Cabezudo-Garc\u00eda P, et al. Cenobamate and clobazam combination as personalized medicine in autoimmune-associated epilepsy with anti-GAD65 antibodies. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200151. https:\/\/doi.org\/10.1212\/NXI.0000000000200151.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1057_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/epd2.70327","author":"MEC Andraus","year":"2026","unstructured":"Andraus MEC, Liem B, Aurangzeb S, et al. NMDAR-antibody encephalitis: seizure semiology and EEG findings. Epileptic Disord. 2026. https:\/\/doi.org\/10.1002\/epd2.70327.","journal-title":"Epileptic Disord"},{"key":"1057_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110835","author":"Y Winter","year":"2026","unstructured":"Winter Y, Dargham RA, Ellwardt E, et al. Quality of life and synergistic combinations of antiseizure medication in patients treated with cenobamate in early therapy lines for focal-onset seizures. Epilepsy Behav. 2026. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110835.","journal-title":"Epilepsy Behav"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01057-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:42:19Z","timestamp":1792665739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01057-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":89,"alternative-id":["1057"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01057-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"22 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Simone Gasparini declares that he has no competing interest. Renzo Guerrini is an Editorial Board member of\n                      Neurology and Therapy\n                      . Renzo Guerrini was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. He declares to serve on scientific advisory boards for Zogenix, Biocodex, GW-Jazz, Angelini, Takeda, Rapport Therapeutics, SK Life Science, Stoke Therapeutics, UCB, and Ethypharm; has received speaker honoraria and travel funding from Zogenix, Biocodex, GW-Jazz, Angelini, Takeda, Rapport Therapeutics, Novartis, SK Life Science, Stoke Therapeutics, UCB, Marinus, Ethypharm, and GRIN Therapeutics; and has served as an investigator for Zogenix, Biocodex, UCB, GRIN Therapeutics, SK Life Science, TEVA, Marinus, Lundbeck, and The Loulou Foundation.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}